Foghorn Therapeutics (FHTX) Cash from Investing Activities (2019 - 2026)

Foghorn Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$17.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 160.27% year-over-year to -$17.7 million; the TTM figure through Mar 2026 stood at $64.9 million (up 335.23% YoY), while the FY2025 annual figure was $112.0 million, up 474.67% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$17.7 million, down from $13.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $46.1 million in Q3 2022, with the low at -$159.4 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $27.1 million (2024), against an average of -$2.1 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 4788.35% in 2022, then surged 674.54% in 2023.
• Foghorn Therapeutics' Cash from Investing Activities stood at -$6.5 million in 2022, then soared by 674.54% to $37.4 million in 2023, then sank by 40.37% to $22.3 million in 2024, then slumped by 40.64% to $13.2 million in 2025, then sank by 233.91% to -$17.7 million in 2026.
• Business Quant data shows FHTX's Cash from Investing Activities at -$17.7 million in Q1 2026, $13.2 million in Q4 2025, and $35.6 million in Q3 2025.